Last reviewed · How we verify
NCT04024176
Gait Analysis in Moderate Hemophiliac Patients (AQM-Hemophile)
NA trial testing Gait analysis in Moderate Hemophilia in 24 participants. Completed in 4 September 2020.
4 September 2020
Quick facts
| Lead sponsor | Nantes University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 24 |
| Start date | 29 November 2019 |
| Primary completion | 4 September 2020 |
| Estimated completion | 4 September 2020 |
| Sites | 4 locations across France |
Drugs / interventions tested
- Gait analysis
Conditions studied
- Moderate Hemophilia — all drugs for Moderate Hemophilia →
- Arthropathy — all drugs for Arthropathy →
Sponsor
Nantes University Hospital
Who can join
18 and older, any sex, with Moderate Hemophilia or Arthropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The management of moderate hemophilia is less codified than those of severe patients; because these patients are theoretically less likely to bleed and therefore less likely to develop arthropathies. Nowaways, the question arises as to the appropriateness of this "symptomatic" management for the prevention of the occurrence of hemophilic arthropathies. Indeed, a significant number of moderate hemophiliacs seems to develop severe arthropathies that cause significant disability. However, because of the very small proportion of these patients in the total number of hemophiliacs, data are lacking on the impact of arthropathies on this population. The investigators therefore propose to include moderate hemophiliac patients in the study to carry out an evaluation of gait, using a gait analysis to determine the consequences of arthropathies, even sub-clinical ones, according to the duration of the disease's progression. In an associated way, the analysis of different clinical (joint assessment; quality of life score;...), radiological (radiographic; ultrasound (synovial thickness)), biological (level of associated factors ; other associated marker), in order to provide a complete picture of the articular situation in these patients with moderate haemophilia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Gait Alteration Due to Haemophilic Arthropathies in Patients with Moderate Haemophilia.
Fouasson-Chailloux A, Leboeuf F, Maugars Y, Trossaert M, et al · · 2022 · cited 7× · PMID 35742774 · DOI 10.3390/ijerph19127527
Verify or expand the search:
- PubMed search for NCT04024176
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gait analysis
Trials testing the same drug.
- NCT07191795 — Uses of Phantom Sensations Induced by Global and Local Modifications of the Prosthetic Socket as Somatosensory Feedback · NA · recruiting
- NCT06107556 — Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury · unknown
- NCT05913934 — Clubfeet and Twins and Gait Analysis · unknown
- NCT05576064 — Is Gait Analysis for Proposed Rotational Deformities a Useful Resource · completed
- NCT06260813 — Biomechanical and Morphological Characterization of PTTD · NA · recruiting
Other Nantes University Hospital trials
Trials by the same sponsor.
- NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
- NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
- NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
- NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
- NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04024176 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
- Last refreshed: 19 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04024176.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing